Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis

Learn more about:
Related Clinical Trial
The Use of Shear Wave Elastography, Transvaginal Ultrasound and Pelvic MRI in the Diagnosis of Adenomyosis Long-term Use of Mifepristone in the Treatment of Adenomyosis Radiofrequency Ablation of Adenomyosis Determination of the Incidence of Endometriosis and or Adenomyosis in Patients Diagnosed With Polycystic Ovary Syndrome, or the Incidence of Polycystic Ovary Syndrome in Patients Diagnosed With Endometriosis and or Adenomyosis The Effect of Adenomoyosis on Pregnancy Outcomes Observational Study of Patients Suffering From Endometriosis and Adenomyosis Factors Associated With Adenomyosis and a Clinical Scoring System for the Diagnosis Quality of Life After Hysterectomy (AdenoQOL) Low Molecular Weight Heparin on the Adenomyosis Patients’IVF-ET Outcome Diagnosis of Adenomyosis Using Ultrasound, Elastography and MRI Clinical and Molecular Study of Endometriosis and Adenomyosis Surgical Success After Laparoscopic vs Abdominal Hysterectomy Electronic Catheter Stethoscope Ovarian Reserve Modification After Lps Hysterectomy With Bilateral Salpingectomy Does 3D Laparoscopy Improve Vaginal Cuff Suture Time? Single-port Access Laparoscopic-assisted Vaginal Hysterectomy Uterine Artery Embolization for Symptomatic Fibroids Oxytocin in MRI-HIFU To Compare to 2-channel and Multiple-channel Single Port Laparoscopic-assisted Vaginal Hysterectomy Effect of Addition of Steroids on Duration of Analgesia Paracervical Block in Laparoscopic Hysterectomy Use of Dexamethasone in Uterine Artery Embolization Treatment of Benign Uterine Disorders Using High Intensity Focused Ultrasound (MR-HIFU) Comparison of Estrogen-progestin Therapy in Continuous Regimen Versus Combination Estrogen-progestin Therapy in Continuous Regimen Plus Levonorgestrel-releasing Intrauterine System (LNG-IUS) Dienogest for Treatment of Adenomyotic Uteri Health-Related QoL Among Women Receiving Hysterectomy in NTUH Development and Validation of EHP-30 (Hong Kong Chinese Version) for Patients With Endometriosis and Adenomyosis Adenomyosis and Ulipristal Acetate Efficacy of Acupuncture on Chronic Pelvic Pain in Women With Endometriosis or Adenomyosis LNG-IUS for Treatment of Dysmenorrhea Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis Adenomyosis: Genomic Mechanisms and Biological Response What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography Comparing Efficacy of Microwave vs Embolization Treatment for Adenomyosis Role of Dienogest in the Treatment of Patient With Symptomatic Adenomyosis Comparison of the Operation and Medical Treatment of Endometriosis and Adenomyosis A Prospective Study of Diagnostic Accuracy of Ultrasound Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis A Multi-omics Study of Adenomyosis Norwegian Adenomyosis Study II: Gene Expression Profiling of Adenomyosis Levonorgestrel Intrauterine System and Adenomyosis Validation of the Adenomyosis Calculator Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri Modified Downregulation for Women With Adenomyosis of the Uterus Prior to Frozen-thawed Embryo Transfer. New Inflammation Markers for Distinguishing Uterine Adenomyosis and Leiomyoma The Association Between Adenomyosis/Uterine Myoma and Lower Urinary Tract Symptoms High-intensity Focused Ultrasound in Treatment of Uterine Adenomyosis Evaluation of Therapeutic Effect and Safety of Mifepristone in the Treatment of Adenomyosis Norwegian Adenomyosis Study III: Peristalsis Histopathological Diagnosis of Adenomyosis Norwegian Adenomyosis Study I Vaginal Bromocriptine for Treatment of Adenomyosis Levonorgestrel-releasing Intrauterine System for the Treatment of Symptomatic Adenomyosis

Brief Title

Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis

Official Title

A Phase II, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Proof of Concept Study With an Interim Futility Analysis of Epelsiban in Patients With Adenomyosis

Brief Summary

      The primary objective of the study is to assess the efficacy, safety, and tolerability of
      epelsiban compared with placebo in treatment of women with adenomyosis.

      This is a 12-week, randomized, double-blind, placebo-controlled, parallel group study with an
      interim futility analysis. Subjects will be randomized 1:1:1 to receive 75 milligrams (mg) of
      epelsiban three times daily (TID), 200 mg of epelsiban TID, or placebo TID. The study will be
      composed of three periods: screening, treatment, and follow-up and the total time a subject
      will be in the study will be approximately 6 months.

Study Phase

Phase 2

Study Type


Primary Outcome

Mean percent change from baseline in monthly menstrual blood loss (MBL) to menstrual Cycle 3

Secondary Outcome

 Change from baseline in monthly menstrual blood loss (MBL) at menstrual Cycle 1, 2, and 3





Study Arms / Comparison Groups

 Epelsiban 75 mg
Description:  Approximately 24 subjects will receive 75 mg of epelsiban three times a day (TID) via oral administration


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

July 2016

Completion Date

October 2016

Primary Completion Date

October 2016

Eligibility Criteria

        Inclusion Criteria:

          -  Eighteen to 55 years of age, inclusive

          -  Pre-menopausal with a history of regular menstrual cycles every 21-35 days and without
             intermenstrual bleeding heavier than spotting and staining.

          -  Females with adenomyosis confirmed on magnetic resonance imaging (MRI), - Females with
             heavy menstrual bleeding .

          -  Willing and able to collect all menstrual cycle by-products for each cycle from
             screening to follow up.

          -  Not pregnant as confirmed by a negative serum human chorionic gonadotropin

        Exclusion Criteria:

          -  A female subject will not be eligible for inclusion in this study if any of the
             following criteria apply:

          -  Abnormal gynecological examination other than adenomyosis and/or breast examination
             requiring intervention within six months of study start

          -  Abnormal endometrial biopsy within six months of starting study treatment.

          -  History of an endometrial ablation within 12 months of starting study treatment.

          -  Uterine artery embolization within six months of starting study treatment.

          -  Prior major uterine procedures or any other significant uterine abnormalities on MRI
             (previous caesarean section, dilation and curettage, and diagnostic hysteroscopy are

          -  Confirmed rectovaginal endometriosis in women who have undergone a prior laparoscopy.

          -  Active pelvic infection or current use of an intrauterine device within three months
             of screening.

          -  Women with a history of transfusion for heavy menstrual bleeding within the past 2
             years or history of postpartum hemorrhage.

          -  Any uterine dimension >20 centimeter (cm).

          -  Other major causes of heavy menstrual bleeding -

          -  Use within 3 months or anticipated use of medications that modify reproductive

          -  Use or anticipated use of the following drugs: anticoagulants aminocaproic acid ,or
             any other medications that affect menstrual bleeding such as tranexamic acid.

          -  Use of daily opioid pain medications other than with menses.

          -  Hemoglobin <8 grams (g)/deciliter.

          -  History of bleeding disorder or known presence of acquired or inherited thrombophilia,
             (sickle cell trait individuals are not excluded).




18 Years - 55 Years

Accepts Healthy Volunteers



GSK Clinical Trials, , 

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Responsible Party


Study Sponsor


Study Sponsor

GSK Clinical Trials, Study Director, GlaxoSmithKline

Verification Date

January 2017